Kynurenine pathway dysregulation in attention-deficit hyperactivity disorder: Impact on N-methyl-D-aspartate receptors and phasic dopamine maturation

Abstract

Recent evidence highlights a significant shift in the kynurenine pathway (KP) toward a neurotoxic profile in medication-naïve children with attention-deficit/hyperactivity disorder (ADHD). This article contextualizes these metabolic alterations – specifically the reduction in kynurenic acid (KYNA) and the elevation of the quinolinic acid (QUIN)/KYNA ratio – as active drivers of neurodevelopmental pathology rather than mere biomarkers. We hypothesize that chronic KP dysregulation disrupts the “N-methyl-D-aspartate-dopamine link”, where KYNA deficiency leads to N-methyl-D-aspartate receptor disinhibition, subsequently interfering with the phasic dopaminergic signaling essential for executive function. Furthermore, the convergence of these metabolic signatures with those found in affective disorders provides a biological rationale for the high rates of depressive comorbidity in ADHD. We discuss the potential for targeting the KP, particularly through kynurenine 3-monooxygenase inhibition, to restore glutamatergic homeostasis. Crucially, we address the role of blood-brain barrier permeability in ADHD as a factor that may exacerbate the impact of peripheral kynurenine metabolites on central nervous system function.

Key Words: Kynurenine pathway; Dopamine; N-methyl-D-aspartate receptor; Neuroinflammation; Blood-brain barrier

Core Tip: The metabolic imbalance characterized by low kynurenic acid and high quinolinic acid in drug-naïve attention-deficit/hyperactivity disorder patients suggests a systemic failure of neuroprotective mechanisms. This biochemical environment likely disrupts N-methyl-D-aspartate receptor modulation, interfering with the maturation of dopaminergic pathways. The increased permeability of the blood-brain barrier in attention-deficit/hyperactivity disorder may allow these peripheral metabolites to exert a more direct influence on central neurotransmission, making the kynurenine pathway a primary therapeutic target.

INTRODUCTION

The kynurenine pathway (KP) serves as the primary metabolic route for over 90% of tryptophan (TRP) catabolism and is increasingly recognized as a crucial player in neuroinflammation and the neurobiology of attention-deficit/hyperactivity disorder (ADHD)[1-5]. Evidence indicates that KP alterations contribute to a shift from homeostatic neuroprotection to glutamatergic excitotoxicity in the brain, offering a potential explanation for the incomplete response to dopamine agonists in some patients[6]. The KP pathway bifurcates into neuroprotective and neurotoxic branches, and in ADHD, this balance is disturbed[1-5]. Drug-free children and adults with ADHD exhibit significantly lower levels of serum kynurenic acid (KYNA). KYNA acts as an antagonist at the N-methyl-D-aspartate (NMDA) glutamate receptors, thus acting as a neuroprotective agent[7]. Conversely, higher levels of the upstream metabolite kynurenine (KYN) have been found in drug-naive children, suggesting increased enzymatic activity – driven by neuroinflammation – that shifts metabolism towards the neurotoxic arm[7]. Increased quinolinic acid (QUIN) (a neurotoxic NMDA type glutamate receptor agonist) alongside decreased KYNA suggests a shift towards glutamatergic excitotoxicity, where the brain lacks sufficient protection against excessive NMDA receptor activation[1,3,5]. To clarify the clinical significance of these findings in ADHD, we examine the roles of “NMDA-dopamine-related” processes, neuroinflammation in metabolic shunts, and KP changes as a common biological vulnerability in mood disorders comorbid with ADHD.

THE KP AND INFLAMMATORY SHUNTING

The KP is highly sensitive to immune-inflammatory triggers. Enzymes such as indoleamine 2,3-dioxygenase (IDO), found in the immune system and the brain, and TRP dioxygenase in the liver, serve as the rate-limiting steps for converting TRP into KYN[2]. In the presence of pro-inflammatory cytokines, IDO activity is upregulated[8], effectively “shunting” TRP away from serotonin synthesis and toward the production of TRYCATs (TRP catabolites)[9-13].

The meta-analysis by Cavaleri et al[1] underscores that drug-free children with ADHD often exhibit higher blood KYN concentrations, likely resulting from this increased enzymatic activity. However, the subsequent metabolism of KYN determines the neurobiological outcome. KYN is converted into KYNA by KYN aminotransferase isozymes, or into neurotoxic compounds like 3-hydroxykynurenine (3-HK) and QUIN via the KYN 3-monooxygenase (KMO) branch[14-16]. The evidence in ADHD consistently shows a failure of the KYN aminotransferase branch, leading to a deficit in KYNA – a molecule acknowledged for its neuroprotective effects through the competitive inhibition of ionotropic glutamate receptors[13-17].

The KP is not merely a degradative route for TRP; it is a sophisticated regulatory system for the immune response, neuronal signaling, and oxidative stress management. Enzymes such as IDO and TRP dioxygenase are upregulated by pro-inflammatory cytokines (e.g., interferon-gamma, tumor necrosis factor-alpha). In ADHD, this “shunting” leads to an accumulation of 3-HK and QUIN, which are potent inductors of reactive oxygen species, thereby increasing oxidative stress in developing neurons (Figure 1)[17-20].

Figure 1 Neuroinflammation and tryptophan shunting in attention-deficit/hyperactivity disorder pathophysiology. This diagram outlines how immune-inflammatory triggers redirect tryptophan metabolism. In attention-deficit/hyperactivity disorder, increased enzymatic activity “shunts” tryptophan away from serotonin, favoring the production of neurotoxic compounds like quinolinic acid. The failure of the kynurenine aminotransferase branch to produce sufficient neuroprotective kynurenic acid creates an imbalance that contributes to neuronal oxidative stress and glutamate dysregulation. ADHD: Attention-deficit/hyperactivity disorder; IDO: Indoleamine 2,3-dioxygenase; IFN-γ: Interferon-gamma; KAT: Kynurenine aminotransferase; KMO: Kynurenine 3-monooxygenase; KYN: Kynurenine; TDO: Tryptophan dioxygenase; TNF-α: Tumor necrosis factor-alpha; ROS: Reactive oxygen species.

DETAILED INTERACTION: KYNA, QUIN, AND THE NMDA RECEPTOR

The NMDA receptor is a heterotetrameric ion channel that requires the binding of two ligands for activation: Glutamate at the GluN2 subunit and a co-agonist (glycine or D-serine) at the GluN1 subunit[21-25]. KYNA is the only known endogenous antagonist that specifically targets the glycine-binding site (strychnine-insensitive) of the NMDA receptor[26]. By competitively binding to this site, KYNA acts as a “molecular thermostat”, preventing excessive calcium influx and excitotoxicity. Conversely, QUIN is a potent NMDA receptor agonist that binds directly to the glutamate recognition site. When the QUIN/KYNA ratio increases, as observed in drug-naïve ADHD patients, the receptor is hit by a “double whammy”: (1) An increase in agonistic stimulation (via QUIN); and (2) A loss of antagonistic regulation (due to KYNA deficiency)[27-31].

Furthermore, KYNA is a potent antagonist of the alpha-7 nicotinic acetylcholine receptor, which is localized on presynaptic glutamatergic terminals. By antagonizing these receptors, KYNA further reduces glutamate release. Therefore, a reduction in KYNA leads to a “disinhibition” of the entire glutamatergic system, creating a high-noise environment that interferes with synaptic plasticity (Table 1). KYNA acts as a “molecular thermostat” by antagonizing the glycine site of the NMDA receptor. In contrast, QUIN serves as an NMDA agonist. The imbalance in ADHD creates a high-noise environment. Furthermore, the reduction of KYNA results in the disinhibition of alpha 7nAchR, leading to excessive glutamate release and subsequent excitotoxicity[32-35].

Table 1 Differential effects of kynurenine metabolites on neuroreceptor sites.

Metabolite	Target receptor	Action	Resulting effect in ADHD
KYNA	NMDA (glycine site)	Competitive antagonist	Decreased in ADHD; loss of neuroprotection
KYNA	Alpha-7 nicotinic acetylcholine receptor	Antagonist	Decreased in ADHD; increased glutamate release
Quinolinic acid	NMDA (glutamate site)	Potent agonist	Increased relative to KYNA; excitotoxicity
3-hydroxykynurenine	Mitochondrial complex II	Inhibitor	Induces oxidative stress and reactive oxygen species production

ADHD: Attention-deficit/hyperactivity disorder; KYNA: Kynurenic acid; NMDA: N-methyl-D-aspartate.

THE “TWO-HIT” HYPOTHESIS AND DOPAMINERGIC MATURATION

NMDA receptors are essential for the induction of long-term potentiation and long-term depression, which are the cellular substrates of learning and executive function[36]. In the “two-hit” hypothesis of neurodevelopment, an initial metabolic or genetic insult creates a state of vulnerability. A deficiency in KYNA (hit 1) leads to a loss of the “molecular brake” on NMDA receptors. When combined with environmental stress or further inflammatory insults (hit 2), the resulting excitotoxicity can “drown out” the precision of synaptic plasticity[37-40].

This dysregulation is not limited to glutamate. NMDA receptors are critical for the regulation of midbrain dopamine neurons. Chronic NMDA overactivation can disrupt the phasic dopamine bursts required for reward processing and goal-directed behavior[41]. If the dopaminergic system is forced to develop in an unfavorable KYN environment, its ability to respond to task-relevant stimuli is diminished, manifesting as the hallmark symptoms of ADHD. Lower KYNA levels have been shown to dampen the neuronal activity of midbrain dopamine neurons[42], suggesting that the “hypodopaminergic” state often cited in ADHD may be secondary to primary KP dysregulation.

BRIDGING THE GAP: BLOOD-BRAIN BARRIER PERMEABILITY IN ADHD

A major challenge is translating peripheral blood measurements into central nervous system (CNS) activity. Both KYNA and QUIN exhibit relatively poor permeability across a healthy blood-brain barrier (BBB) under normal physiological conditions. Traditionally, this has led researchers to argue that peripheral levels may not accurately reflect the neurochemical environment of the brain[43-46]. However, this limitation must be re-evaluated in the context of ADHD. Recent neurobiological evidence suggests that the BBB is significantly more permeable in individuals with ADHD compared to healthy controls. Chronic low-grade systemic inflammation – manifested by the very KP shifts discussed here – can compromise the integrity of the tight junctions that form the BBB in six studies[44-49].

In this state of increased permeability, peripheral KYN (which crosses the BBB easily via the large neutral amino acid transporter, L-type amino acid transporter 1) can flood the brain, providing more substrate for local QUIN synthesis by activated microglia. Moreover, the increased “leakiness” of the BBB in ADHD patients may allow peripheral QUIN and other pro-inflammatory cytokines to enter the CNS directly. This suggests that the peripheral metabolic signature of low KYNA and high QUIN is not just a correlation, but likely a direct contributor to central neuroinflammation and NMDA dysregulation[50-52].

The translation of peripheral measurements to CNS activity is supported by evidence that the BBB is significantly more permeable in ADHD patients. Chronic inflammation may degrade tight junction proteins like claudin-5. Notably, this “leakiness” appears particularly relevant in pediatric populations where the BBB is still maturing, though it remains a factor in adults with chronic systemic inflammation. This increased permeability allows peripheral QUIN and cytokines to directly access the CNS, exacerbating the metabolic shift[53].

COMORBID DEPRESSION: THE SHARED KYN LINK

The biochemical profiles observed in ADHD (low KYNA, high QUIN/KYNA) strongly coincide with the “kynurenin shunt” observed in major depressive disorder[54]. In states of chronic inflammation, IDO activation persists, leading to the accumulation of neurotoxic metabolites that can induce oxidative stress and hippocampal atrophy – features common to both severe ADHD and depression[55].

The presence of this metabolic signature in drug-naïve children suggests a biological predisposition to affective disorders long before clinical symptoms of depression manifest. Specifically, QUIN-mediated neurotoxicity in the anterior cingulate cortex may serve as a contributing factor to the emotional dysregulation and depressive symptoms frequently observed in the adult ADHD population. By identifying this “KYN link”, clinicians may eventually be able to use these metabolites as prognostic markers for future psychiatric risk.

KP AS A METABOLIC LINK TO MULTI-SYSTEMIC NETWORK DYSFUNCTION IN ADHD

The traditional dopamine hypothesis, while foundational, increasingly fails to account for the heterogeneous clinical presentation of ADHD and the significant percentage of patients who remain non-responsive to stimulant medication. Current neurobiological perspectives suggest that ADHD is not a localized deficiency but a systemic failure of network coordination involving an interplay between neurotransmitter imbalances, impaired reward processing, and disrupted biological rhythms[56]. Integrating the KP into this framework provides a metabolic bridge that explains how peripheral inflammation and TRP catabolism may drive the multifaceted neural circuit dysfunctions observed in the disorder[57].

METABOLIC MODULATION OF GLUTAMATERGIC AND GABAERGIC IMBALANCE

One of the most salient features of ADHD neurobiology is the reported increase in neuronal excitability, particularly within the frontal lobe and striatum, often attributed to elevated glutamate levels and a concomitant decrease in inhibitory GABAergic signaling. The KP serves as a primary regulator of this excitatory-inhibitory balance. The meta-analytic evidence indicating significantly lower levels of KYNA in ADHD patients suggests a loss of endogenous NMDA receptor antagonism. Under normal physiological conditions, KYNA acts as a “molecular brake” on glutamatergic transmission; its reduction in ADHD likely facilitates the hyper-excitability of cortical circuits[58]. This lack of glutamate regulation may impede the efficient “pruning” and stabilization of synapses during development, leading to the structural reductions observed in frontal-striatal and frontal-cerebellar circuits. Furthermore, because the KP is the dominant route for TRP degradation, its dysregulation may indirectly impact the serotonin system. The shunting of TRP into an overactive but inefficient KYN branch – characterized by high KYN but low KYNA – potentially limits the substrate availability for serotonin synthesis, aligning with findings of low venous serotonin and metabolic gene mutations in ADHD populations[59,60].

IMPACT ON BRAIN NETWORK COORDINATION AND REWARD PROCESSING

The transition between the default mode network (DMN) and task-positive network (TPN) is critical for sustained attention and the suppression of mind-wandering. In ADHD, the failure to inhibit DMN activity during task execution is a hallmark of network dysfunction[61]. The KP may influence this coordination through its effects on midbrain dopaminergic neurons. Research indicates that KYNA levels modulate the firing patterns of dopamine neurons in the ventral tegmental area, which projects to the prefrontal cortex and nucleus accumbens – the core hubs of the reward and motivation systems. A deficiency in KYNA, as identified in the meta-analysis, may dampen the neuronal response to reward prediction errors. This metabolic “blunting” could explain the clinical observation that ADHD symptoms worsen in the absence of high-novelty or immediate rewards; the brain’s internal signaling of task importance is chemically attenuated. Consequently, the smooth transition from a resting state (DMN) to an active, task-oriented state (TPN) is disrupted because the metabolic environment cannot support the necessary dopaminergic and noradrenergic surge required for cognitive engagement[62].

EPIGENETIC SUSCEPTIBILITY AND THE GENE-ENVIRONMENT INTERACTION

The high heritability of ADHD (60%-80%) and its interaction with environmental stressors (G × E) find a plausible mechanism in the KP. Environmental triggers such as prenatal stress, tobacco exposure, or lead – all associated with altered DNA methylation of genes like DAT1 – are also potent activators of the immune-inflammatory response. Pro-inflammatory cytokines induce the enzyme IDO, which accelerates the conversion of TRP to KYN. This suggests that the KP may be an epigenetic effector: Environmental toxins may “switch on” a state of chronic, subsyndromal inflammation that permanently shifts TRP metabolism[8,63]. This shift creates a neurochemical milieu characterized by higher levels of potentially neurotoxic catabolites and lower levels of protective agents like KYNA, thereby increasing the risk of neurodevelopmental abnormalities. In this context, the KP acts as a transducer that converts environmental insults into long-term changes in neural circuit architecture[8].

CIRCADIAN DYSREGULATION AND BIOLOGICAL RHYTHMS

The high prevalence of sleep disorders and circadian misalignment in ADHD (70%-75%) suggests a profound disruption of the biological clock. TRP is the common precursor for both the KP and the synthesis of melatonin via the serotonin pathway. A metabolic bias toward KYN production, particularly in the presence of inflammatory stimuli, may reduce the pool of TRP available for melatonin production, contributing to delayed sleep phase syndrome and insomnia[5,64]. Furthermore, the KP itself exhibits circadian rhythmicity; the enzymes and metabolites involved fluctuate according to the internal clock. The identified imbalances in KYN and KYNA may therefore be both a cause and a consequence of the disrupted biological rhythms seen in ADHD patients[5,64]. This suggests that the “misalignment” of the biological clock in ADHD is not merely a behavioral issue but a fundamental metabolic disturbance that exacerbates the instability of neural networks.

PHARMACOLOGICAL MODULATION OF THE KP: METHYLPHENIDATE

The traditional understanding of methylphenidate (MPH) focuses almost exclusively on its capacity to block the reuptake of dopamine and norepinephrine, thereby enhancing signal transmission in the prefrontal cortex and striatum. However, integrating KP dynamics into the neurobiological model of ADHD reveals that stimulants may also function as metabolic stabilizers[65]. By shifting the balance between neurotoxic and neuroprotective TRP catabolites (TRYCATs), pharmacological interventions address the underlying structural and network instabilities that simple dopamine replacement cannot fully resolve. This metabolic shift is particularly evident in the restoration of the “neuroprotective buffer” provided by KYNA.

Stimulant-induced restoration of KYNA and glutamatergic stability

A critical component of the ADHD “metabolic signature” is a deficiency in KYNA, which leaves NMDA receptors under-regulated and prone to glutamate-induced hyper-excitability. Clinical data suggests that prolonged treatment with MPH is associated with a significant increase in peripheral KYNA concentrations. This increase effectively restores the endogenous antagonism of NMDA receptors, providing a biochemical “brake” that dampens the noisy, high-frequency neural firing characteristic of the ADHD brain. By stabilizing the glutamatergic environment, MPH likely supports the functional integrity of the frontal-striatal circuits, facilitating better behavioral inhibition and reducing the motor restlessness associated with hyperactivity. Furthermore, the capacity of MPH to modulate the KYN-to-TRP (KYN/TRP) ratio suggests a mild immunomodulatory effect[66]. By reducing the systemic inflammatory signals that drive the conversion of TRP into KYN, stimulants prevent the “shunting” of essential amino acids away from the serotonin system, thereby preserving the neurochemical resources necessary for the regulation of the DMN.

Synergy between dopaminergic enhancement and metabolic protection

The efficacy of MPH in addressing reward prediction errors is significantly enhanced by its interaction with the KP. Because KYNA acts as a modulator of midbrain dopamine neuron firing, the stimulant-induced rise in KYNA levels likely sensitizes the brain’s reward circuitry. This create a synergistic effect where the direct increase in synaptic dopamine is supported by a metabolic environment that favors stable, clear reward signaling. This dual-action mechanism explains why treated patients often show improved engagement with low-novelty tasks; the brain’s internal valuation system is reinforced both by the presence of dopamine and the reduction of the “background noise” caused by KYN-driven excitability. This protection extends to the frontal-cerebellar circuits, which are particularly susceptible to oxidative stress caused by the “neurotoxic branch” of the KP (such as 3-HK). By favoring the neuroprotective branch, MPH acts as a prophylactic against the long-term structural thinning of these vital regions (Figure 2).

Figure 2 Metabolic and circuit-level synergy of stimulant therapy in attention-deficit/hyperactivity disorder. Methylphenidate enhances the brain’s internal valuation system through a two-pronged mechanism: (1) Direct dopaminergic enhancement in the prefrontal cortex and striatum; and (2) Kynurenine pathway modulation. The resulting increase in kynurenic acid sensitizes reward circuitry while filtering out kynurenine-driven “noise”. This dual action reinforces reward signaling and behavioral inhibition, explaining the improved engagement with low-novelty tasks and the reduction in motor restlessness characteristic of successful stimulant treatment. ADHD: Attention-deficit/hyperactivity disorder; PFC: Prefrontal cortex; 3-HK: 3-hydroxykynurenine.

EMERGING NON-STIMULANT HORIZONS: KMO INHIBITORS AND SPECIFIC KP MODULATORS

Given that a substantial portion of the ADHD population does not respond optimally to stimulants, the discovery of the KP opens the door for a new class of non-stimulant therapies that target metabolic enzymes directly[67]. KMO inhibitors represent a frontier in this field. Unlike traditional stimulants, KMO inhibitors do not interact directly with the dopamine transporter; instead, they block the enzymatic path that leads to the production of neurotoxic QUIN. This blockage forces a metabolic “detour” that raises endogenous KYNA levels. Such a targeted approach could theoretically provide the neuroprotective benefits of MPH without the side effects often associated with dopaminergic drugs, such as appetite suppression or sleep disturbance (Figure 3)[68-70]. By selectively increasing the neuroprotective-to-neurotoxic ratio, these emerging therapies aim to stabilize the ADHD connectome from the bottom up, correcting the metabolic “noise” that disrupts network coordination and biological rhythms (Table 2).

Figure 3 The “metabolic detour”: Selective kynurenine pathway modulation to restore network coordination. A diagrammatic representation of the therapeutic potential of kynurenine 3-monooxygenase inhibitors in attention-deficit/hyperactivity disorder. Unlike stimulants that act on neurotransmitter transporters, kynurenine 3-monooxygenase inhibitors correct metabolic “noise” by preventing the accumulation of N-methyl-D-aspartate-agonistic neurotoxins. The resulting increase in the “neuroprotective buffer” (kynurenic acid) facilitates bottom-up stabilization of biological rhythms and network coordination, offering a precision-medicine approach for patients who are refractory to standard stimulant treatments. ADHD: Attention-deficit/hyperactivity disorder; DAT: Dopamine transporter; KMO: Kynurenine 3-monooxygenase; KP: Kynurenine pathway.

Table 2 Comparative mechanisms of attention-deficit/hyperactivity disorder pharmacotherapy.

Feature	Methylphenidate	KMO inhibitors
Primary target	Dopamine/norepinephrine transporters	KMO enzyme
Mechanism	Increases synaptic catecholamines	Blocks neurotoxic branch; raises KYNA
Circuit impact	Direct enhancement of reward signaling	Reduction of metabolic “noise” and excitotoxicity
Side effect profile	Potential appetite/sleep disruption	Targeted metabolic shift (lower systemic risk)
Role in kynurenine pathway	Indirect stabilizer (increases KYNA)	Direct pathway modulator

KMO: Kynurenine 3-monooxygenase; KYNA: Kynurenic acid.

CONCLUSION

In conclusion, integrating the KP into ADHD neurobiology necessitates a shift from a neurotransmitter-centric model to a metabolic-network model. The systemic reduction of neuroprotective KYNA, alongside inflammation-driven KYN elevation, provides a biochemical basis for glutamate-mediated hyperexcitability, impaired reward processing, and DMN/TPN dysregulation. By linking peripheral inflammation and amino acid catabolism to frontal-striatal and circadian dysfunction, the KP emerges as a primary regulator of the ADHD “connectome”. Future therapeutic strategies must move beyond catecholamine replacement to prioritize modulating the KP. This approach aims to restore the metabolic equilibrium essential for stable neural circuit function. As a dual-action agent, MPH reinforces this model by providing immediate dopamine enhancement while potentially stabilizing long-term TRP catabolism.